BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10537365)

  • 1. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline.
    Uckun FM; Ek O; Liu XP; Chen CL
    Clin Cancer Res; 1999 Oct; 5(10):2954-62. PubMed ID: 10537365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
    Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
    Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacokinetics and anti-anaphylactic activity of the novel mast cell inhibitor 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131).
    Malavija R; Chen CL; Liu XP; Uckun FM
    Am J Ther; 2001; 8(1):35-9. PubMed ID: 11304656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative high-performance liquid chromatographic method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P131).
    Chen CL; Malaviya R; Chen H; Liu XP; Uckun FM
    J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):205-12. PubMed ID: 10360439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner.
    Linwong W; Hirasawa N; Aoyama S; Hamada H; Saito T; Ohuchi K
    Br J Pharmacol; 2005 Jul; 145(6):818-28. PubMed ID: 15852029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.
    Uckun FM; Dibirdik I; Qazi S; Yiv S
    Arzneimittelforschung; 2010; 60(4):210-7. PubMed ID: 20486472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97).
    Malaviya R; Chen CL; Navara C; Malaviya R; Liu XP; Keenan M; Waurzyniak B; Uckun FM
    J Pharmacol Exp Ther; 2000 Dec; 295(3):912-26. PubMed ID: 11082424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
    Uckun FM; Roers BA; Waurzyniak B; Liu XP; Cetkovic-Cvrlje M
    Blood; 2002 Jun; 99(11):4192-9. PubMed ID: 12010825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.
    Cetkovic-Cvrlje M; Roers BA; Waurzyniak B; Liu XP; Uckun FM
    Blood; 2001 Sep; 98(5):1607-13. PubMed ID: 11520814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase.
    Uckun FM; Dibirdik I; Qazi S
    Arzneimittelforschung; 2010; 60(4):218-25. PubMed ID: 20486473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation.
    Uckun FM; Thoen J; Chen H; Sudbeck E; Mao C; Malaviya R; Liu XP; Chen CL
    Drug Metab Dispos; 2002 Jan; 30(1):74-85. PubMed ID: 11744615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1).
    Cetkovic-Cvrlje M; Dragt AL; Uckun FM
    Arzneimittelforschung; 2003; 53(9):648-54. PubMed ID: 14558439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
    Malaviya R; Zhu D; Dibirdik I; Uckun FM
    J Biol Chem; 1999 Sep; 274(38):27028-38. PubMed ID: 10480916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice.
    Chen CL; Malaviya R; Navara C; Chen H; Bechard B; Mitcheltree G; Liu XP; Uckun FM
    Pharm Res; 1999 Jan; 16(1):117-22. PubMed ID: 9950289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).
    Narla RK; Liu XP; Klis D; Uckun FM
    Clin Cancer Res; 1998 Oct; 4(10):2463-71. PubMed ID: 9796979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases.
    Sahin K; Yabas M; Orhan C; Tuzcu M; Sahin TK; Ozercan IH; Qazi S; Uckun FM
    Expert Opin Ther Targets; 2020 Apr; 24(4):379-387. PubMed ID: 32106727
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
    Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
    Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
    Messinger Y; Yanishevski Y; Ek O; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
    Clin Cancer Res; 1998 Jan; 4(1):165-70. PubMed ID: 9516966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of atherosclerosis in apolipoprotein E-deficient mice with 4-(3-Bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), a potent inhibitor of triglyceride synthesis.
    Trieu VN; Liu XP; Chen CL; Uckun FM
    J Cardiovasc Pharmacol; 2000 Feb; 35(2):179-88. PubMed ID: 10672848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An inhibitor of Janus kinase 3:4-(4-hydroxyphenylamino)-6, 7-dimethoxyquinazolin-1-ium chloride methanol solvate.
    Sudbeck EA; Jennissen JD; Liu XP; Uckun FM
    Acta Crystallogr C; 2000 Oct; 56 ( Pt 10)():1282-3. PubMed ID: 11025327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.